Key points

  • Xenon Pharmaceuticals Chief Executive Officer Ian Mortimer bought $1.12 million of company stock on September 30th, 2026. The purchase covered 30,000 shares.
  • Every share was reported at a single price of $37.38. There was no spread across the trade, which points to one execution rather than a staggered program.
  • The buying arrived through one Form 4 filing. No other insider purchases sit alongside it in this window.
  • Xenon last traded at $38.02, above the price Mortimer paid. The company carries a market capitalization of $3,681,873,152.

Ian Mortimer, Chief Executive Officer of Xenon Pharmaceuticals Inc., reported an open-market purchase of 30,000 shares on September 30th, 2026. The shares were bought at $37.38 each, for a reported total of $1.12 million.

Xenon Pharmaceuticals sits in the Pharmaceutical Preparations group and carries a market capitalization of $3,681,873,152. The stock last traded at $38.02, a level above the price recorded in the filing.

What the filing shows

The record here is narrow and clean. One filing, one date, one price. The 30,000 shares were all transacted at $37.38, with no high end and low end to separate, which is what a single block execution typically looks like on a Form 4.

The dollar figure, $1.12 million, is the reported value of that purchase and nothing more. It is an open-market buy by the sitting Chief Executive Officer rather than an award, a grant, or an exercise of previously issued options. That distinction is the main reason purchases of this kind are tracked separately from the rest of insider activity.

What the insiders did

One name appears in this window and it is Mortimer. The count of filings is one, so there is no cluster of officers and directors stepping in together on the same days, and no pattern of repeat buying across weeks to point at.

That matters for how much weight the event carries. A solitary purchase, even a seven figure one from the top of the house, is a single data point. Readers who track insider flow usually want to know whether a buy is isolated or whether it sits inside a run of filings from several people. In this case it is isolated.

It is also worth noting what the filing does not say. A Form 4 records the transaction, the date, the price and the quantity. It does not record motive. Nothing in the document explains the purchase, and no interpretation of intent should be read into it beyond the transaction itself.

Where the price sits

Mortimer's reported price of $37.38 compares with a last traded price of $38.02. The purchase was therefore made below where the shares currently change hands, though the gap is small and the elapsed time is short.

Against a market capitalization of $3,681,873,152, a $1.12 million purchase is a modest sum in absolute terms relative to the company. The relevance of insider buys is rarely their size against the float. It is the direction of the trade and the identity of the person making it.

What that leaves

The clearest facts are the simplest ones. The Chief Executive Officer of a mid-capitalization biopharmaceutical company put $1.12 million of his own money into 30,000 shares at $37.38 on September 30th, 2026, and did so in a single reported filing.

Everything beyond that requires watching. Whether other officers and directors follow, whether Mortimer adds to the position in later windows, and whether the shares hold above the $37.38 level are all questions the current record cannot answer. Pharmaceutical Preparations names tend to move on clinical and regulatory calendars rather than on insider flow, and a single purchase does not change that.

For now the takeaway is factual rather than directional. One buy, one buyer, one price, and a last traded price of $38.02 that sits above it.

Sources: SEC Form 4 filings submitted via EDGAR and reviewed by InsiderBuying.com, covering the transaction dated September 30th, 2026.

Informational only, not investment advice.